The condition of insomnia: Etiopathogenetic considerations and their impact on treatment practices

International Review of Psychiatry

Volumn 17, Issue 4, 2005, Pages 255-262

  Dikeos, Dimitris G ^a   Soldatos, Constantin R ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; BROTIZOLAM; ESTAZOLAM; FLUNITRAZEPAM; FLURAZEPAM; HERBACEOUS AGENT; HYPNOTIC AGENT; LORMETAZEPAM; MELATONIN; MIDAZOLAM; NEUROLEPTIC AGENT; NITRAZEPAM; QUAZEPAM; SEDATIVE AGENT; TEMAZEPAM; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOPICLONE;

AMNESIA; AROUSAL; BEHAVIOR; CHRONICITY; DISEASE PREDISPOSITION; DOCTOR PATIENT RELATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERANCE; DRUG UTILIZATION; HUMAN; INSOMNIA; LIFE EVENT; MENTAL DISEASE; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOTHERAPY; REBOUND INSOMNIA; REVIEW; SIDE EFFECT; SLEEP TIME; SLEEP WAKING CYCLE; STRESS;

COGNITIVE THERAPY; HUMANS; HYPNOTICS AND SEDATIVES; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOMATOFORM DISORDERS;

EID: 21744442297     PISSN: 09540261     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540260500104466     Document Type: Review

References (98)

1. Adam, K., Tomeny, M., & Oswald, I. (1986). Physiological and psychological differences between good and poor sleepers. Journal of Psychiatric Research, 20, 301-316.
2. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R). Washington, DC: American Psychiatric Association Press.
3. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association Press.
4. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV). Washington, DC: American Psychiatric Association Press.
5. American Sleep Disorders Association (1990). International classification of sleep disorders. Rochester, MN.
6. Association of Sleep Disorders Centres (1979). Diagnostic classification of sleep and arousals disorders. Sleep, 2, 1-137.
7. Bailey, L., Ward, M., & Musa, M. N. (1994). Clinical pharmacokinetics of benzodiazipines. Journal of Clinical Pharmacology, 34, 804-811.
8. Barkin, R. L., Chor, P. N., Braun, B. G., & Schwer, W. A. (1999). A trilogy case review highlighting the clinical and pharmacologic applications of mirtazapine in reducing polypharmacy for anxiety, agitation, insomnia, depression, and sexual dysfunction. The Primary Care Companion to the Journal of Clinical Psychiatry, 1, 142-145.
9. Beer, B., Ieni, J. R., Wu, W. H., Clody, D., Amorusi, P., Rose, J., et al. (1994). A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. Journal of Clinical Pharmacology, 34, 335-344.
10. Benca, R. M. (2001). Consequences of insomnia and its therapies. Journal of Clinical Psychiatry, 62(Suppl 10), 33-38.
11. Bixler, E. O., Kales, A., Manfredi, R. L., Vgontzas, A. N., Tyson, K. L., & Kales, J. D. (1991). Next-day memory impairment with triazolam use. Lancet, 337(8745), 827-831.
12. Bixler, E. O., Kales, A., Soldatos, C. R., Kales, J. D., & Healey, S. (1979). Prevalence of sleep disorders in the Los Angeles Metropolitan Area. American Journal of Psychiatry, 136, 1257-1262.
13. Bixler, E. O., Vgontzas, A. N., Lin, Hm., Vela-Bueno, A., & Kales, A. (2002). Insomnia in central Pennsylvania. Journal of Psychosomatic Research, 53(1), 589-592.
14. Bliwise, D. L. (1991). Treating insomnia: Pharmacological and non-pharmacological approaches. Journal of Psycho active Drugs, 23(4), 335-341.
15. Bonnet, M. H., & Arand, D. L. (1995). 24-Hour metabolic rate in insomniacs and matched normal sleepers. Sleep, 18(7), 581-588.
16. Bonnet, M. H., & Arand, D. L. (2003). Insomnia, metabolic rate and sleep restoration. Journal of Internal Medicine, 254, 23-31.
17. Bootzin, R. R., Epstein, D., & Wood, J. M. (1991). Stimulus control instructions. In P. Hauri (Ed.), Case studies in insomnia (pp. 19-28). New York, NY: Plenum Press.
18. Bootzin, R. R., & Perlis, M. L. (1992). Non-pharmacologic treatments of insomnia. Journal of Clinical Psychiatry, 53, 37-41.
19. Broman, J. E., & Hetta, J. (1994). Electrodermal activity in patients with persistent insomnia. Journal of Sleep Research, 3(3), 165-170.
20. Dikeos, D. G., & Soldatos, C. R. (2002). The pharmacotherapy of insomnia: Efficacy and rebound with hypnotic drugs. Primary Care Companion to the Journal of Clinical Psychiatry, 4(Suppl 1), 27-32.
21. Fernandez, C., Maradeix, V., Gimenez, F., Thuillier, A., & Farinotti, R. (1993). Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metabolism and Disposition, 21, 1125-1128.
22. Ford, D., & Kamerow, D. (1989). Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? Journal of American Medical Association, 262, 1479-1484.
23. Freedman, R. R., & Sattler, H. L. (1982). Physiological and psychological factors in sleep-onset insomnia. Journal of Abnormal Psychology, 91, 380-389.
24. Gillin, J. C., Spinweber, C. L., & Johnson, L. C. (1989). Rebound insomnia: A critical review. Journal of Clinical Psychopharmacology, 9, 161-172.
25. Greenblatt, D. J., & Shader, R. I. (1985). Clinical pharmacokinetics of the benzodiazepines. In D. E. Smith & D. R. Wesson (Eds), The benzodiazepines: Current standards for medical practice. Lancaster, England: MTP Press.
26. Greenblatt, D. J., Harmatz, J. S., von Molthe, L. L., Ehrenberg, B. L., Harrel, L., Corbett, K., et al. (1998). Comparative kinetics and dynamics of zaleplon, zolpidem and placebo. Clinical Pharmacology and Therapeutics, 64, 553-561.
27. Greenson, R. R. (1967). The technique and practice of psychoanalysis. New York: International Universities Press.
28. Gustavson, L. E., & Carrigan, P. J. (1990). The clinical pharmacokinetics of single doses of estazolam. The American Journal of Medicine, 88, 2S-5S.
29. Hajak, G., Rodenbeck, A., Voderholzer, U., Riemann, D., Cohrs, S., Hohagen, F., et al. (2001). Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study. Journal of Clinical Psychiatry, 62, 453-463.
30. Harvey, L., Inglis, S. J., & Espie, C. A. (2002). Insomniacs' reported use of CBT components and relationship to long-term clinical outcome. Behavioral Research Therapy, 40, 75-83.
31. Hauri, P., & Fisher, J. (1986). Persistent psychophysiologic (learned) insomnia. Sleep, 9(1), 38-53.
32. Hauri, P. J. (1991). Case studies in insomnia. New York: Plenum Press.
33. Hauri, P. J. (2002). Psychological and psychiatric issues in the etiopathogenesis of insomnia. The Primary Care Companion to the Journal of Clinical Psychiatry, 4(Suppl 1), 17-20.
34. Healy, E. S., Kales, A., Monroe, L. J., Bixler, E. O., Champerin, K., & Soldatos, C. R. (1981). Onset of insomnia: Role of life-stress events. Psychosomatic Medicine, 43, 439-451.
35. Kales, A., & Kales, J. D. (1984). Evaluation and treatment of insomnia. New York: Oxford University Press.
36. Kales, A., Bixler, E. O., Vela-Bueno, A., Cadieux, R. J., Soldatos, C. R., & Kales, J. D. (1984a). Biopsychobehavioral correlates of insomnia, III: Polygraphic findings of sleep difficulty and their relationship to psychopathology. International Journal of Neuroscience, 23, 43-55.
37. Kales, A., Caldwell, A. B., Soldatos, C. R., Bixler, E. O., & Kales, J. D. (1983). Biopsychobehavioral correlates of insomnia. II. Pattern specificity and consistency with the Minnesota Multiphasic Personality Inventory. Psychosomatic Medicine, 45, 341-356.
38. Kales, A., Soldatos, C. R., & Kales, J. D. (1981). Sleep disorders: Evaluation and management in the office setting. In S. Arieti & H. K. H. Brody (Eds), American Handbook of Psychiatry (Vol. 7, pp. 423-454, 2nd Edn). New York: Basic Books Inc.
39. Kales, A., Soldatos, C. R., & Kales, J. D. (1987). Sleep disorders: Insomnia, sleepwalking, night terrors, nightmares, and enuresis. Annals of Internal Medicine, 106, 582-592.
40. Kales, A., Vgontzas, A. N., & Bixler, E. O. (1995). Hypnotic drugs. In A. Kales (Ed.), Handbook of experimental pharmacology: Pharmacology of sleep (pp. 116, 345-385). New York: Springer.
41. Kales, J. D., Kales, A., Bixler, E. O., Soldatos, C. R., Cadieux, R. J., Kashurba, G. J., et al. (1984b). Biopsychobehavioral correlates of insomnia, V: Clinical characteristics and behavioral correlates. American Journal of Psychiatry, 141, 1371-1376.
42. Karacan, I., Thornby, J. I., Anch, M., Holzer, C. E., Warheit, G. J., Schwab, J. J., et al. (1976). Prevalence of sleep disturbance in a primarily urban Florida county. Social Science and Medicine, 10, 239-244.
43. Karasu, T. B. (1980). Psychotherapies: An overview. In T. B. Karasu & L. Bellak (Eds), Specialized techniques in individual psychotherapy (pp. 3-32). New York: Brunner Mazel.
44. Katz, D. A., & McHorney, C. A. (1998). Clinical correlates of insomnia in patients with chronic illness. Archives of Internal Medicine, 158, 1099-1107.
45. Lader, M. (1992). Rebound insomnia and newer hypnotics. Psychopharmacology, 108, 248-255.
46. Lader, M. (2002). Managing dependence and withdrawal with newer hypnotic medications in the treatment of insomnia. The Primary Care Companion to the Journal of Clinical Psychiatry, 4(Suppl 1), 33-37.
47. Langtry, H. D., & Benfield, P. (1990). Zolpidem, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs, 40, 291-313.
48. Liljenberg, B., Almwvist, M., Hetta, J., Roos, B.-E., & Agren, H. (1989). Affective disturbance and insomnia: A population study. European Journal of Psychiatry, 3, 91-98.
49. Mendelson, W. B. (1997). A critical evaluation of the hypnotic efficacy of melatonin. Sleep, 20, 916-919.
50. Mendelson, W. B., Roth, T., Cassella, J., Roehrs, T., Walsh, J. K., Woods, J. H., et al. (2004). The treatment of chronic insomnia: Drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Medicine Reviews, 8, 7-17.
51. Monroe, L. J. (1967). Psychological and physiological differences between good and poor sleepers. Journal of Abnormal Psychology, 72, 255-264.
52. Morin, C. M. (1993). Insomnia: Psychological assessment and management. New York: Guilford Press.
53. Morin, C. M. (2002). Contributions of cognitive-behavioral approaches to the clinical management of insomnia. The Primary Care Companion to the Journal of Clinical Psychiatry, 4(Suppl 1), 21-26.
54. Morin, C. M., Colecchi, C. A., Stone, J., Sood, R., & Brink, D. (1999a). Behavioral and pharmacological therapies for late-life insomnia: A randomized clinical trial. Journal of the American Medical Association, 281, 991-999.
55. Morin, C. M., Culbert, J. P., & Schwartz, S. M. (1994). Non-pharmacological interventions for insomnia: A meta-analysis of treatment efficacy. The American Journal of Psychiatry, 151, 1172-1180.
56. Morin, C. M., Hauri, P. J., Espie, C. A., Spielman, A., Buysse, D. J., & Bootzin, R. R. (1999b). Non-pharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep, 22, 1134-1156.
57. Mouret, J., Ruel, D., Maillard, F., & Bianchi, M. (1990). Zopiclone versus triazolam in insomniac geriatric patients: A specific increase in delta sleep with zopiclone. International Clinical Psychopharmacology, 5(Suppl 2), 47-55.
58. Murtagh, D. R. R., & Greenwood, K. M. (1995). Identifying effective psychological treatments for insomnia: A meta-analysis. Journal of Consulting and Clinical Psychology, 63, 79-89.
59. Nielsen, G. (1990). Brief integrative dynamic psychotherapy for insomnia. Systematic evaluation of two cases. Psychotherapy and Psychosomatics, 54, 187-192.
60. O'Hanlon, J. (2002). Residual effects on memory and psychomotor performance of zaleplon and other hypnotic drugs. The Primary Care Companion to the Journal of Clinical Psychiatry, 4(Suppl 1), 38-44.
61. Ohayon, M. M., & Roth, T. (2001). What are the contributing factors for insomnia in the general population? Journal of Psychosomatic Research, 51(6), 745-755.
62. Partinen, M., Kaprio, J., Koskenvuo, M., & Langinvainio, H. (1983). Sleeping habits, sleep quality, and use of sleeping pills: A population study of 31,140 adults in Finland. In C. Guilleminault & E. Lugaresi (Eds), Sleep/wake disorders: Natural history, epidemiology, and long-term evolution (pp. 29-35). New York, NY: Raven Press.
63. Perlis, M. L., Kehr, E. L., Smith, M. T., Andrews, P. J., Orff, H., & Giles, D. E. (2001a). Temporal and stage-wise distribution of high frequency EEG activity in patients with primary and secondary insomnia and in good sleeper controls. Journal of Sleep Research, 10, 93-104.
64. Perlis, M. L., Merica, H., Smith, M. T., & Giles, D. E. (2001b). Beta EEG activity and insomnia. Sleep Medicine Reviews, 5, 363-374.
65. Pillitteri, J. L., Kozlowski, L. T., Person, D. C., & Spear, M. E. (1994). Over-the-counter sleep aids: Widely used but rarely studied. Journal of Substance Abuse, 6, 315-323.
66. Quera-Salva, M. A., Orluc, A., Goldenberg, F., & Guilleminault, C. (1991). Insomnia and use of hypnotics: Study of a French population. Sleep, 14, 386-391.
67. Rodenbeck, A., Cohrs, S., Jordan, W., Huether, G., Ruther, E., & Hajak, G. (2003). The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (Berl), 170, 423-428.
68. Roehrs, T., Vogel, G., & Roth, T. (1990). Rebound insomnia: Its determinants and significance. The American Journal of Medicine, 88(Suppl 3A), 39-42.
69. Roehrs, T., Zorick, F., Koshorek, G. L., Wittig, R., & Roth, T. (1983). Effects of acute administration of brotizolam in subjects with disturbed sleep. British Journal of Clinical Pharmacology, 16(Suppl 2), 371-376.
70. Roth, T., Hajak, G., & Üstün, T. B. (2001). Consensus for the pharmacological management of insomnia in the new millennium. International Journal of Clinical Practice, 55(1), 42-52.
71. Sack, R. L., Brandes, R. W., Kendall, A. R., & Lewy, A. J. (2000). Entrainment of free-running circadian rhythms by melatonin in blind people. New England Journal of Medicine, 343, 1070-1077.
72. Sateia, M. J., & Nowell, P. D. (2004). Insomnia. Lancet, 564(9449), 1959-1973.
73. Scharf, M. B., Fletcher, K., & Graham, J. P. (1988). Comparative amnesic effects of benzodiazepine hypnotic agents. Journal of Clinical Psychiatry, 49, 134-137.
74. Simon, G. E., & Vonkorff, M. (1997). Prevalence, burden, and treatment of insomnia in primary care. The American Journal of Psychiatry, 154(10), 1417-1423.
75. Soldatos, C. R. (1991). Insomnia. In R. Rakel (Ed.), Conn's Current Therapy (pp. 29-31, 43rd Edn). Philadelphia: Saunders Co.
76. Soldatos, C. R. (1994). Insomnia in relation to depression and anxiety: Epidemiologic considerations. Journal of Psychosomatic Research, 38(Suppl 1), 3-8.
77. Soldatos, C. R. (2002). Diagnosis and treatment of insomnia at the start of the 21st century. The Primary Care Companion to the Journal of Clinical Psychiatry, 4(Suppl 1), 3-7.
78. Soldatos, C. R., & Bergiannaki, J. D. (2000). Sleep in depression and the effects of antidepressants on sleep. In U. Halbreich & S. A. Montgomery (Eds), Pharmacotherapy for mood, anxiety and cognitive disorders (pp. 255-271). Washington DC: American Psychiatric Press Inc.
79. Soldatos, C. R., & Dikeos, D. G. (1995). Neuroleptics, antihistamines and anti-Parkinsonian drugs: Effects on sleep. In A. Kales (Ed.), Pharmacology of sleep (pp. 443-464). Berlin: Springer.
80. Soldatos, C. R., & Dikeos, D. G. (2003). An integrative approach to the management of insomnia. Current Opinion in Psychiatry, 16(Suppl. 2), 93-99.
81. Soldatos, C. R., Allaert, F. A., Ohta, T., & Dikeos, D. G. (2005). How do individuals sleep around the world? Results from a single-day survey in ten countries. Sleep Medicine (in press).
82. Soldatos, C. R., Dikeos, D. G., & Whitehead, A. (1999). Tolerance and rebound insomnia with rapidly eliminated hypnotics: A meta-analysis of sleep laboratory studies. International Clinical Psychopharmacology, 14, 287-303.
83. Soldatos, C. R., Kales, A., & Kales, J. D. (1979). Management of insomnia. Annual Review of Medicine, 30, 301-312.
84. Soldatos, C. R., Kales, A., Bixler, E. O., Scharf, M. B., & Kales, J. D. (1978). Hypnotic effectiveness of sodium salicylamide with short-term use: Sleep laboratory studies. Pharmacology, 16, 193-198.
85. Spielman, A. J., & Glovinsky, P. B. (1991). The varied nature of insomnia. In P. Hauri (Ed.), Case studies in insomnia (pp. 1-15). New York, NY: Plenum Press.
86. Spielman, A. J., Saskin, P., & Thorpy, M. J. (1987). Treatment of chronic insomnia by restriction of time in bed. Sleep, 10, 45-56.
87. Sutton, D. A., Moldofsky, H., & Badley, E. M. (2001). Insomnia and health problems in Canadians. Sleep, 24(6), 665-670.
88. Sweetwood, H., Grant, I., Kripke, D. F., Gerst, M. S., & Yager, J. (1980). Sleep disorder over time: Psychiatric correlates among males. British Journal of Psychiatry, 136, 456-462.
89. Tan, T., Kales, J. D., Kales, A., Soldabus, C. R. & Bixler, E. O. (1984). Biopsychobehavioral correlates of insomnia, IV: Diagnoses based on DSM-III. The American Journal of Psychiatry, 141, 356-362.
90. Üstün, T. B., Privett, M., Lecrubier, Y., Weiller, E., Simon, G., Korten, A., et al. (1996). Form, frequency and burden of sleep problems in general health care: A report from the WHO Collaborative Study on Psychological Problems in General Health Care. European Psychiatry, 11(Suppl 1), 5-11.
91. Vgontzas, A. N., & Chrousos, G. P. (2002). Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: Multiple interactions and disturbances in sleep disorders. Endocrinology and Metabolism Clinics of North America, 31, 15-36.
92. Vgontzas, A. N., & Kales, A. (1999). Sleep and its disorders. Annual Review of Medicine, 50, 387-400.
93. Vgontzas, A. N., Bixler, E. O., Lin, H. M., Prolo, P., Mastorakos, G., Vela-Bueno, A., et al. (2001). Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: Clinical implications. Journal of Clinical Endocrinology and Metabolism, 862, 3787-3794.
94. Vogel, G. W., & Vogel, F. (1983). Effect of midazolam on sleep of insomniacs. British Journal of Clinical Pharmacology, 16(Suppl 1), 103S-108S.
95. Walsh, J., Fry, J., Erwin, C., Scharf, M., Roth, T., & Vogel, G. (1998). Efficacy and tolerability of 14-day administration of zaleplon 5mg and 10mg for the treatment of primary insomnia. Clinical Drug Investigation, 16, 347-354.
96. Walsh, J. K., Vogel, G. W., Scharf, M. B., Erman, M., Erwin, C. W., Schweitzer, P. K., et al. (2000). A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Medicine, 1, 41-49.
97. Weissman, M. M., Greenwald, S., Nino-Murcia, G., & Dement, W. C. (1997). The morbidity of insomnia uncomplicated by psychiatric disorders. General Hospital Psychiatry, 19(4), 245-250.
98. World Health Organization (1992). The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization.